| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
|
John, A.
|
|
|
34 |
10 |
p. 829-830
|
artikel
|
| 2 |
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆
|
Parsons, H.A.
|
|
|
34 |
10 |
p. 899-906
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
34 |
10 |
p. iii
|
artikel
|
| 4 |
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
|
Loibl, S.
|
|
|
34 |
10 |
p. 849-866
|
artikel
|
| 5 |
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe ☆
|
Bayle, A.
|
|
|
34 |
10 |
p. 934-945
|
artikel
|
| 6 |
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
|
Jhaveri, K.
|
|
|
34 |
10 |
p. 885-898
|
artikel
|
| 7 |
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
González-Martín, A.
|
|
|
34 |
10 |
p. 833-848
|
artikel
|
| 8 |
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
|
Felip, E.
|
|
|
34 |
10 |
p. 907-919
|
artikel
|
| 9 |
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 ☆
|
Besse, B.
|
|
|
34 |
10 |
p. 920-933
|
artikel
|
| 10 |
Table of Contents
|
|
|
|
34 |
10 |
p. i-ii
|
artikel
|
| 11 |
The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
|
Wei, T.
|
|
|
34 |
10 |
p. 948-949
|
artikel
|
| 12 |
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
|
Tarantino, P.
|
|
|
34 |
10 |
p. 949-950
|
artikel
|
| 13 |
Treatment of evolving cancers will require dynamic decision support
|
Strobl, M.A.R.
|
|
|
34 |
10 |
p. 867-884
|
artikel
|
| 14 |
Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors
|
Adotévi, O.
|
|
|
34 |
10 |
p. 831-832
|
artikel
|
| 15 |
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
|
Fasching, P.A.
|
|
|
34 |
10 |
p. 951-953
|
artikel
|
| 16 |
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors
|
Gouda, M.A.
|
|
|
34 |
10 |
p. 946-948
|
artikel
|
Tijdschrift beschrijving